

Clearbridge inks exclusive partnership in China to establish and market laboratory developed tests for circulating tumour cells

- *Its partner is Hunan Agen Medicine Laboratory Technology Co., Ltd which specialises in the development and commercialisation of laboratory tests*
- *Both parties will collaborate to develop circulating tumour cells tests and market them in China*

SINGAPORE – 23 July 2018 – Clearbridge Health Limited (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (明策集团), a healthcare company with a focus on the delivery of precision medicine in Asia, has entered into an exclusive partnership with Hunan Agen Medicine Laboratory Technology Co., Ltd (“Agen Lab”), on the commercialisation for clinical application of circulating tumour cell (“CTC”) technology.

Based in the Changsha High-Tech Development Zone, Agen Lab provides multidisciplinary diagnostics, including clinical cellular and molecular genetics, clinical pathology, clinical immunology, clinical biochemistry, and advanced equipment such as Next Generation Sequencing.

Under the partnership agreement, the Group will provide the ClearCell® FX1 System, a CTC enrichment platform and other ancillary materials and consumables, as well as installation and training to Agen Lab and assist in the development of laboratory developed tests (“LDT”). Subsequently, the Group will be marketing the tests exclusively in China.

The ClearCell® FX1 System, driven by CTChip® FR was designed and manufactured in Singapore by the Group’s associated company, Clearbridge BioMedics Pte. Ltd.. It is one of the world’s first automated cell retrieval systems that can enrich wholly intact and viable CTCs from small amounts of blood in a relatively short time. This means that researchers and clinicians can use these insights to provide timely, tailored treatment options.

Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, said: *“This exclusive collaboration draws on the strength of both partners – our Group’s technology and Agen Lab’s laboratory expertise. We believe it will result in a suite of LDTs that will significantly benefit the healthcare industry and also patients in the form of more accurate and broader diagnosis and screening of CTCs, which will lead to more targeted treatment.*

As a healthcare company with a focus on precision medicine, this partnership is strongly in line with our corporate objective to enable healthcare professionals to gain better insights into their patients’ conditions by promoting application research and leveraging technology to achieve more accurate diagnosis of CTCs.”

Professor Meng Tao (孟涛教授), Founder and Chief Scientist of Agen Lab, said: *“China is a country with a high incidence rate of cancer and this number is increasing year on year. Agen Lab has been committed to cell and molecular biology technology, with a focus particularly in ctDNA and CTC-based liquid biopsy in the field of cancer precision medicine technology and product development. We are optimistic about our partnership with Clearbridge. With the introduction of the ClearCell® FX1 CTC enrichment system, we are confident that the clinical application prospects of CTC enrichment and downstream detection technology will result in the accurate diagnosis and treatment of cancers.*

Through this strategic cooperation, we will be able to provide the latest and most advanced diagnostic services to scientific researchers and clinicians in the field of oncology via Agen Lab’s medical laboratory service network throughout China, promoting the rapid development of China’s precision medicine industry.”

-- END --

About Clearbridge Health Limited

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients.

For more information, please visit us at www.clearbridgehealth.com.

About Hunan Agen Medicine Laboratory Technology Co., Ltd

Hunan Agen Medicine Laboratory Technology Co., Ltd is located in the industrial development district of Changsha. Founded by Xi’an Agen Gene Health Technology Co., Ltd, the company focuses on precision medicine, and is committed to developing state-of-the-art technology in the gene and health industry in China. Hunan Agen’s subsidiary, Changsha Agen Fang Sheng Medicine Laboratory is licensed by the National Health Authority. At 2,700 square meters, Changsha Agen is known for its four medical laboratory specialties; clinical cellular and molecular genetics, clinical pathology, clinical immunology and clinical biochemistry. Its main businesses include the genotyping of personalised medication for various fatal diseases and early tumour screening via liquid biopsy, with core technologies in liquid biopsy, bioinformatics analysis, disease prevention and intervention post gene tests.

For more information, please visit www.agen.com.cn.





Issued by and on behalf of Clearbridge Health Limited

August Consulting

Tel: +65 6733 8873

Silvia Heng, silviaheng@august.com.sg

Wrisney Tan, wrisneytan@august.com.sg

Zavier Ong, zavierong@august.com.sg

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST").

The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.